VASOGEN'S ACCLAIM RESULTS TO BE PRESENTED AT MEETING

Vasogen has announced that the pivotal Phase III ACCLAIM trial of its Celacade technology in advanced chronic heart failure will be presented at the upcoming World Congress of Cardiology 2006 in Barcelona, Spain.

The ACCLAIM (Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy) trial enrolled 2,400 patients at 176 cardiac centers throughout North America, Europe, and Israel. The study is a double-blind, placebo-controlled trial designed to further assess the impact of Vasogen's Celacade technology on the risk of death and cardiovascular hospitalizations in advanced chronic heart failure patients and to support the regulatory approval process in North America and commercialization in North America and Europe.